StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX – Free Report) in a research note released on Sunday. The brokerage issued a hold rating on the specialty ...

The FDA has approved a supplemental New Drug Application (sNDA) for Cumberland Pharmaceuticals Inc.’s Acetadote (N-acetylcysteine for injection) product, an intravenous (IV) formulation of ...

Acetadote is supplied as a 20% solution (200mg/mL) in a 30mL single-dose vial that must be diluted prior to intravenous administration. Total injection volume will vary based on the patient’s ...

The Food and Drug Administration (FDA) has approved a new dosing regimen for Acetadote ® (n-acetylcysteine [NAC] for injection), an antidote for acetaminophen overdose. According to Cumberland ...

Thanks mostly to FDA approval of a supplementary New Drug Application (sNDA) for Acetadote (N-acetylcysteine for injection), Cumberland stock has been on a monumental run in December 2024.

FDA approved a simplified Acetadote dosing regimen, reducing errors and serious reactions while maintaining effectiveness. Acetadote addresses liver injury from acetaminophen toxicity, the leading ...

On Monday, the FDA approved Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) supplemental New Drug Application (sNDA) for its Acetadote (N-acetylcysteine for injection) product. Acetadote is an ...

Acetadote is used in hospital emergency departments to prevent or lessen the risk of liver damage following an acetaminophen overdose, which is often caused by overuse of over-the-counter pain ...